ACSL3 and steatosis: These findings support the notion that not only the quantity but also the quality and metabolic routing of LDs determine whether steatosis remains metabolically benign or is coupled to hepatocyte injury, and they position ACSL3 as a key regulator at the interface between LD dynamics and hepatocellular stress.